Literature DB >> 25195694

BRCA1 and BRCA2 mutations and the risk for colorectal cancer.

V Sopik1, C Phelan, C Cybulski, S A Narod.   

Abstract

Women who carry a BRCA1 or BRCA2 mutation are at high risk of breast and ovarian cancer, and may be at moderately increased risk of other cancer types. This review examines studies to date that have evaluated the risk of BRCA1 and BRCA2 mutations for colorectal cancer. Accurate knowledge of colorectal cancer risk in BRCA1/2 carriers is important, because colonoscopy screening can prevent colorectal cancer through the removal of adenomatous polyps. Most studies that have identified an increased risk for colorectal cancer in BRCA1/2 mutation carriers were in high-risk cancer families, while studies that found no association were conducted in specific populations and involved the analysis of founder mutations. A recent prospective study of 7015 women with a BRCA1 or BRCA2 mutation identified significant fivefold increased risk of colorectal cancer among BRCA1 mutation carriers younger than 50 years [standardized incidence ratio (SIR): 4.8; 95% CI: 2.2-9], but not in women with a BRCA2 mutation or in older women. Based on this evidence, women with BRCA1 mutations should be counseled about their increased risk for early-onset colorectal cancer, and offered colonoscopy at 3- to 5-year intervals between the ages of 40 and 50 years, and should follow population guidelines thereafter.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BRCA1; BRCA2; aspirin; colonoscopy; colorectal cancer; prevention

Mesh:

Year:  2014        PMID: 25195694     DOI: 10.1111/cge.12497

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  22 in total

1.  Identification of differentially expressed genes and their upstream regulators in colorectal cancer.

Authors:  H Y Liu; C J Zhang
Journal:  Cancer Gene Ther       Date:  2017-04-14       Impact factor: 5.987

2.  Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers.

Authors:  Efrat Dagan; Daphna Birenbaum-Carmeli; Eitan Friedman; Baruch Feldman
Journal:  J Genet Couns       Date:  2017-03-06       Impact factor: 2.537

3.  Identification of a novel GREM1 duplication in a patient with multiple colon polyps.

Authors:  Danielle B McKenna; Jeroen Van Den Akker; Alicia Y Zhou; Lauren Ryan; Annette Leon; Robert O'Connor; Payal D Shah; Anil K Rustgi; Bryson W Katona
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

4.  Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.

Authors:  Haley Streff; Jessica Profato; Yuanqing Ye; Denise Nebgen; Susan K Peterson; Claire Singletary; Banu K Arun; Jennifer K Litton
Journal:  Oncologist       Date:  2016-06-15

Review 5.  Germline genetic landscape of pediatric central nervous system tumors.

Authors:  Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

6.  COEXPEDIA: exploring biomedical hypotheses via co-expressions associated with medical subject headings (MeSH).

Authors:  Sunmo Yang; Chan Yeong Kim; Sohyun Hwang; Eiru Kim; Hyojin Kim; Hongseok Shim; Insuk Lee
Journal:  Nucleic Acids Res       Date:  2016-09-26       Impact factor: 16.971

7.  Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.

Authors:  Willemina R R Geurts-Giele; Victorien M T van Verschuer; Carolien H M van Deurzen; Paul J van Diest; Rute M S M Pedrosa; J Margriet Collée; Linetta B Koppert; Caroline Seynaeve; Winand N M Dinjens
Journal:  Mod Pathol       Date:  2016-09-09       Impact factor: 7.842

Review 8.  Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis.

Authors:  Brandie Heald; Heather Hampel; James Church; Beth Dudley; Michael J Hall; Maureen E Mork; Aparajita Singh; Elena Stoffel; Jessica Stoll; Y Nancy You; Matthew B Yurgelun; Sonia S Kupfer
Journal:  Fam Cancer       Date:  2020-07       Impact factor: 2.375

9.  Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Authors:  Avital Lev; Safoora Deihimi; Elena Shagisultanova; Joanne Xiu; Amriti R Lulla; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

10.  From BRCA1 to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes.

Authors:  Emma R Woodward; Elke M van Veen; D Gareth Evans
Journal:  Breast Care (Basel)       Date:  2021-03-31       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.